complexity need not be complex

Major events

May 2014

FinaXiom enters a Joint Venture for property financing. Gains a £50m mandate for a prestigeous London development.


March 2014

FinaXiom develops the application of Standby Capital to CCPs.

 2011 - 2013

FinaXiom becomes an Appointed Representative of West Hill Corporate Finance, starts Guernsey development and targets US$10bn facility and receives a “fatwa’ declaring the Standby Capital product Shariah. Develops Standby Capital for financial institutions. Key regulators are advised of Standby Capital properties.

Capital Facility

FinaXiom aims to build a facility to initialise a new asset class of Standby Capital that can then become liquid through a secondary trading platform. Spawned by the deleveraging and regulatory impacts on the financial community by the Credit Crisis FinaXiom estimate that there is a global need of up to US$5 trillion in equity focused capital. The FinaXiom Standby Capital product is a cost effective instrument that responds automatically to adverse events. As such it is not solely focused on financial institutions as it applies to any project where unforseeable events perturb sound strategies and immediate extra liquidity is required.

Risk Pricing

In order to support its pricing approach FinaXCiom has created its own economic framework comprising a triangulation of existing and its own models. It is essential to protect investors, and issuer alike, against changes in a dynamic economy whether this be management's strategies or economic volatility. The pricing system encompasses not only existing methods but also a view of the risk dynamics within global networks, the activities of agents and how they change with time. Investors will be able to monitor these models as a dynamically updated set of scenarios.

Business Model

Focus on core competence. Choices to investor and issuer

As a result of redesigning the economic model FinaXiom has also created a facility that reduces the friction costs to investors and gives them choices over investment profiles until issuer drawdown. The issuer likewise has a choice, the initial risk review is priced separately to but included within the capital facility. Should the issuer choose, they can settle only for the risk review but it must stay confidential in its assumptions and conclusions - we don't want to educate the competion do we?